Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) has signed a funded Manufacturing Services Agreement with CytoImmune Therapeutics to restart production of ACP-01, a stem cell therapy for cardiovascular diseases. The agreement is funded by issuing 30,140,000 common shares of Hemostemix at $0.05 each to CytoImmune. It covers the production of the first 22 ACP-01 therapies, which Hemostemix will sell for $1,100,000 ($50,000 each).
The companies aim to produce the first ACP-01 therapy by Q1 2025. Hemostemix expects to generate substantial cash flow from treating 480 no-option patients annually. The company is also closing a private placement of up to $2,000,000 from the sale of 40 Million Units at $0.05 each, with proceeds used for sales, marketing, and working capital.
Hemostemix announced it has been granted the trademark 'Your Fountain of Youth' by the Swiss Trademark Office, a significant milestone for the company's intellectual property portfolio.
CEO Thomas Smeenk highlighted the positive results from ACP-01, their cardiovascular treatment, with a 27% improvement in LVEF% and notable reductions in ulcer size, amputation, and mortality rates in clinical trials.
Additionally, Hemostemix will make a 2023 interest payment of $226,688.25 to debenture holders via 2,229,616 shares at $0.101671 per share, subject to regulatory approval and a four-month hold period under Canadian securities laws.
Hemostemix announced a strategic partnership with CytoImmune Therapeutics to re-establish ACP-01 production at CytoImmune's facility in Puerto Rico. The company secured $1,800,000 in financing commitments through a private placement at $0.05 per unit. CytoImmune will subscribe for $1,370,000 worth of these units. The partnership aims to scale production of ACP-01, a treatment for chronic limb-threatening ischemia (CLTI), potentially reaching sales of $2 million per month by 2025. Hemostemix's phase II clinical trial showed promising results, with 83% of patients experiencing ulcer healing and pain cessation. The proceeds of the financing will be used for initial batch processing and working capital.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.